Resources & Information

Medscape
February 08, 2024
Brain fog is one of the most common, persistent complaints in patients with long COVID. It affects as many as 46% of patients who also deal with other cognitive concerns like memory loss and difficulty concentrating. Now, researchers believe they know why. A new study has found that these symptoms may be the result of a viral-borne brain injury that may cause cognitive and mental health issues that persist for years. Researchers found that 351 patients hospitalized with severe COVID-19 had evidence of a long-term brain injury a year after contracting the SARS-CoV-2 virus. The findings were based on a series of cognitive tests, self-reported symptoms, brain scans, and biomarkers.

Medpage Today
February 3, 2024

An FDA advisory committee gave generally high marks to the agency’s latest effort to improve the accuracy of pulse oximeters when used in darker-skinned patients, but raised questions about some of the FDA’s proposed premarket clinical trial guidance for pulse oximeter manufacturers.

“I really applaud the efforts of the FDA to reduce disparate bias in pulse oximetry,” said Julian Goldman, MD, an anesthesiologist at Massachusetts General Hospital in Boston. Goldman, a member of the FDA Medical Device Advisory Committee Anesthesiology and Respiratory Therapy Devices Panel, was speaking at Friday’s panel meeting. “This has clearly been a very heavy lift for a long time, and we need to address it.”

Associated Press
February 1, 2024

Women are far more likely than men to get autoimmune diseases, when an out-of-whack immune system attacks their own bodies — and new research may finally explain why.

It’s all about how the body handles females’ extra X chromosome, Stanford University researchers reported Thursday — a finding that could lead to better ways to detect a long list of diseases that are hard to diagnose and treat.

ScienceAlert
January 30, 2024
After six years of searching, researchers from the University of Basel and ETH Zurich in Switzerland have found what might be a crucial weapon in the fight against superbugs: viruses that are able to prey on and kill dangerous bacteria while they’re in a dormant state.

Bacteria go into this sleep mode when they’re low on nutrients or under various kinds of stress. It’s a form of self-protection, which means the bacteria can’t spread or grow. Yet existing in a shut-down state also protects them from threats that hijack their engines, such as viruses or antibiotics.

Bacteria actually spend a lot of time in this inactive state. Up until now, all efforts to discover a type of bacteria-infecting virus (or bacteriophage) that could wipe out hibernating bacteria had been unsuccessful.

Medical News Today
January 28, 2024
Approximately 10%-20% of individuals with a SARS-CoV-2 infection experience lingering symptoms beyond three months after symptom onset. These symptoms referred to as long COVID, can be debilitating, but there is a lack of diagnostic or therapeutic tools. A new study published in Science found that patients experiencing long COVID symptoms six months after the SARS-CoV-2 infection show dysregulation of the blood clotting or coagulation system and the complement pathway, which is a part of the immune system. These changes in the coagulation and immune systems in long COVID patients were shown to predict the persistence of symptoms at six months. They may have the potential for the development of diagnostic tools. Moreover, therapeutics to counter the changes in the blood clotting and immune system could help alleviate long COVID symptoms.

Becker’s Healthcare
January 17, 2024
A new strain of multidrug resistant Pseudocitrobacter bacteria has been identified by researchers. The novel strain was resistant to seven different classes of antibiotics, according to the data, published Jan. 17 in The Journal of Hospital Infection.

Until now, there have been three known species of Pseudocitrobacter bacteria, and the novel isolate was determined to be distinct from all three. The patient from whom the new species was obtained was colonized but not experiencing infection, and therefore did not require antimicrobial treatment.

In clinical testing, the novel isolate, which researchers proposed naming Pseudocitrobacter limerickensis, was resistant to antibiotics including carbapenems, β-lactams, sulfonamides, fluoroquinolones, macrolides, aminoglycosides and cephalosporins.